Healthcare & Medical

Immuno-Oncology Summit 2025

he 13th Annual 2025 Immuno-Oncology Summit brings together professionals in life sciences, pharmaceuticals, clinical research, healthcare, and IT to discuss advances in the development of immune-oncology therapeutics for solid tumors. The conference showcases preclinical and clinical successes grounded in deep biological understanding, including innovations…

Visit the official site

10Voices

4Underwriters

0Exhibitors

0On the bill · sessions

14Companies · in total

§I

The Voices

Programmed at Immuno-Oncology, in alphabetical order.

Biao Zheng, PhD

CEO · BRL Medicine

Carter Caldwell, MBA

Co-Investment Program Director · University of Pennsylvania

David Sommerhalder, MD

Clinical Investigator, Oncology · NEXT Oncology

Karen Chagin, MD

Senior Vice President, Early Stage Development · Adaptimmune

Kristen Meerbrey, PhD

Director of Target Discovery, Therapeutic Innovation Center · Baylor College of Medicine

Margery Ma, PhD

Principal Consultant, NonClinical Regulatory Affairs · Eliquent Life Sciences

Rakesh Dixit, PhD, DABT

President & Founder · Bionavigen Oncology, LLC and Regio Biosciences

Shameer Khader, PhD

Executive Director, Global Head of Data Science, Data Engineering and Computational Biology · Sanofi

Tatiana Novobrantseva, PhD

CSO · NextPoint Therapeutics

Vitalay Fomin, PhD

Co-Founder · Numenos AI

§II

Underwritten By

The houses behind the program. Tiers as disclosed.

Intermission

Part the Second · For the Buyer

An audience of 14 companies, parsed from the program.

“Fourteen companies in attendance.”

The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.

№ 01Fig. 01 — Composition of the House

0All threespeak · spons · exh

4Sponsoringsponsor only

0Exhibitingexhibitor only

10Speakingspeaker only

№ 02Fig. 02 — The Voices, by Seniority

70% of the speakers carry senior titles — C-suite, Founder, VP, or Director-level.

C-suite110%
Founder / Owner220%
VP-level110%
Director / Head of330%
Manager / Lead110%
Other roles220%

Of 10 on the bill · classified by free-text title

№ 03Fig. 03 — The Heaviest in the Room

01IRBMSp
02MisproSp
03Nona BiosciencesSp
04Wuxi App TecSp
05Adaptimmune1V
06Baylor College of Medicine1V
07Bionavigen Oncology, LLC and Regio Biosciences1V
08BRL Medicine1V
09Eliquent Life Sciences1V
10NEXT Oncology1V
11NextPoint Therapeutics1V
12Numenos AI1V
13Sanofi1V
14University of Pennsylvania1V

№ 04Fig. 04 — By Tier

unspecified4

100% of 4